Russia will begin rolling out its first approved drug in the fight against coronavirus which it describes as “a game changer” starting next week, Reuters reported on Monday, citing the country's sovereign wealth fund.
Russia has raced to develop a vaccine and other treatments for the coronavirus as the deadly pandemic has battered its economy and infected more than 400,000 of its citizens. The Russian Direct Investment Fund (RDIF) and the ChemRar biotechnology firm last month touted “promising” clinical trials of a modified version of favipiravir, the generic version of Japanese firm Fujifilm’s anti-flu drug Avigan.
Russia’s Health Ministry has approved the modified antiviral drug, which is registered in Russia as Avifavir, for treating coronavirus patients, and clinics will be able to administer it in tablet form starting June 11, with enough supplies to treat around 60,000 people per month, head of the RDIF Kirill Dmitriev told Reuters.
“We believe this is a game changer. It will reduce strain on the healthcare system, we’ll have fewer people getting into a critical condition, and for 90% of people it eliminates the virus within 10 days,” Reuters quoted Dmitriev as saying.
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.
